Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas - 2Toyota Reports 2.3% Sales Drop as China Weakness Deepens
- 3Surprising links between autism, Alzheimer’s could change how we treat both
- 4Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- 5German inflation soars to 2.7% in March as Iran war drives up prices
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- Pick Your Top Method for starting the Morning
- Countdown to Artemis II: What to know about NASA's moon mission
- Child influencers helped power a booming industry. It's time for a reckoning.
- Haifa refinery said hit in latest Iranian missile barrage
- New method spots signs of Earth's primordial life in ancient rocks
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- Flu concerns grow in US as UK sees more cases among kids
